CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.
Su S, Hu B, Shao J, Shen B, Du J, Du Y, Zhou J, Yu L, Zhang L, Chen F, Sha H, Cheng L, Meng F, Zou Z, Huang X, Liu B.
Su S, et al. Among authors: chen f.
Sci Rep. 2016 Jan 28;6:20070. doi: 10.1038/srep20070.
Sci Rep. 2016.
PMID: 26818188
Free PMC article.